Were Analysts Bearish Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) This Week?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Logo

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Ratings Coverage

Among 3 analysts covering Lexicon Pharmaceuticals (NASDAQ:LXRX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Lexicon Pharmaceuticals has $38 highest and $300 lowest target. $12.60’s average target is 438.46% above currents $2.34 stock price. Lexicon Pharmaceuticals had 13 analyst reports since March 14, 2019 according to SRatingsIntel. The firm has “Buy” rating by Wedbush given on Monday, March 25. The firm earned “Buy” rating on Friday, March 15 by Wedbush. Gabelli downgraded Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) on Thursday, March 14 to “Sell” rating. The stock has “Buy” rating by Citigroup on Tuesday, July 30. The firm has “Buy” rating given on Monday, March 25 by Stifel Nicolaus. Below is a list of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) latest ratings and price target changes.

11/09/2019 Broker: Gabelli Old Rating: Hold New Rating: Buy Upgrade
30/07/2019 Broker: Citigroup Rating: Buy Old Target: $15.0000 New Target: $3.0000 Maintain
29/07/2019 Broker: Inc. – Common Stock Rating: Stifel Nicolaus New Target: $10.0000 4.0000
21/05/2019 Broker: BidaskScore Rating: Sell Downgrade
08/05/2019 Broker: BidaskScore Rating: Hold Upgrade
19/04/2019 Broker: BidaskScore Rating: Sell Downgrade
01/04/2019 Broker: BidaskScore Rating: Sell Downgrade
25/03/2019 Broker: Stifel Nicolaus Rating: Buy New Target: $10 Maintain
25/03/2019 Broker: Needham Rating: Hold Maintain
25/03/2019 Broker: Wedbush Rating: Buy New Target: $34 Maintain

The stock decreased 3.31% or $0.08 during the last trading session, reaching $2.34. About 1.74 million shares traded or 9.52% up from the average. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has declined 89.07% since September 13, 2018 and is downtrending. It has underperformed by 89.07% the S&P500.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company has market cap of $318.07 million. The firm offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. It currently has negative earnings. The Company’s orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain.

More notable recent Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) news were published by: Globenewswire.com which released: “Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi – GlobeNewswire” on September 10, 2019, also Benzinga.com with their article: “26 Stocks Moving in Wednesday’s Pre-Market Session – Benzinga” published on September 11, 2019, Benzinga.com published: “48 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” on September 11, 2019. More interesting news about Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) were released by: Nasdaq.com and their article: “Health Care Sector Update for 09/11/2019: TTOO, LXRX, TLRY, SNY – Nasdaq” published on September 11, 2019 as well as Globenewswire.com‘s news article titled: “Deadline in Lawsuit for Investors in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced by Shareholders Foundation – GlobeNewswire” with publication date: March 05, 2019.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.